• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重度哮喘对低收入家庭的经济影响。

The economic impact of severe asthma to low-income families.

作者信息

Franco R, Nascimento H F, Cruz A A, Santos A C, Souza-Machado C, Ponte E V, Souza-Machado A, Rodrigues L C, Barreto M L

机构信息

Programa para o Controle da Asma e da Rinite Alérgica na Bahia (ProAR), Faculdade de Medicina da Bahia, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.

出版信息

Allergy. 2009 Mar;64(3):478-83. doi: 10.1111/j.1398-9995.2009.01981.x. Epub 2009 Feb 6.

DOI:10.1111/j.1398-9995.2009.01981.x
PMID:19210355
Abstract

BACKGROUND

To estimate the direct and indirect costs of severe asthma and the economic impact of its management to low-income families in Salvador, Brazil.

METHODS

One hundred and ninety-seven patients with severe asthma and referred to a state-funded asthma center providing free treatment were evaluated. At registration, they were asked about family cost-events in the previous year and had a baseline assessment of lung function, symptoms and quality of life. During the subsequent year, they were reassessed prospectively.

RESULTS

One hundred-eighty patients concluded a 12-month follow-up. Eighty-four percent were female patients, and the median family income was US$ 2955/year. Forty-seven percent of family members had lost their jobs because of asthma. Total cost of asthma management took 29% of family income. After proper treatment, asthma control scores improved by 50% and quality of life by 74%. The income of the families increased by US$ 711/year, as their members went back to work. The total cost of asthma to the families was reduced by a median US$ 789/family/year. Consequently, an annual surplus of US$ 1500/family became available.

CONCLUSIONS

Family costs of severe asthma consumed over one-fourth of the family income of the underprivileged population in a middle-income country. Adequate management brings major economic benefit to individuals and families.

摘要

背景

评估重度哮喘的直接和间接成本,以及其管理对巴西萨尔瓦多低收入家庭的经济影响。

方法

对197例重度哮喘患者进行评估,这些患者被转诊至一家提供免费治疗的国立哮喘中心。在登记时,询问他们上一年的家庭成本事件,并对肺功能、症状和生活质量进行基线评估。在随后的一年中,对他们进行前瞻性重新评估。

结果

180例患者完成了12个月的随访。84%为女性患者,家庭收入中位数为每年2955美元。47%的家庭成员因哮喘失去工作。哮喘管理的总成本占家庭收入的29%。经过适当治疗后,哮喘控制评分提高了50%,生活质量提高了74%。由于家庭成员重返工作岗位,家庭收入每年增加711美元。家庭哮喘的总成本中位数每年减少789美元/家庭。因此,每个家庭每年有1500美元的盈余。

结论

在一个中等收入国家,重度哮喘的家庭成本消耗了贫困人群家庭收入的四分之一以上。适当的管理给个人和家庭带来重大经济利益。

相似文献

1
The economic impact of severe asthma to low-income families.重度哮喘对低收入家庭的经济影响。
Allergy. 2009 Mar;64(3):478-83. doi: 10.1111/j.1398-9995.2009.01981.x. Epub 2009 Feb 6.
2
Cost-effectiveness analysis of a state funded programme for control of severe asthma.一项由国家资助的重症哮喘控制项目的成本效益分析。
BMC Public Health. 2007 May 17;7:82. doi: 10.1186/1471-2458-7-82.
3
Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.布地奈德/福莫特罗用于丹麦哮喘维持和缓解治疗的成本效益——基于五项随机对照试验的成本效益分析
Clin Respir J. 2009 Jul;3(3):169-80. doi: 10.1111/j.1752-699X.2009.00134.x.
4
A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain.布地奈德/福莫特罗维持和缓解治疗与西班牙哮喘管理常规最佳实践的比较。
J Asthma. 2011 Oct;48(8):839-47. doi: 10.3109/02770903.2011.611954.
5
Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.布地奈德/福莫特罗作为维持和缓解治疗与固定剂量联合策略的比较——一项加拿大的经济学评估。
Can J Clin Pharmacol. 2008 Summer;15(2):e165-76. Epub 2008 Jun 1.
6
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma.布地奈德/福莫特罗维持和缓解治疗:对哮喘气道炎症的影响
Eur Respir J. 2008 May;31(5):982-9. doi: 10.1183/09031936.00104007. Epub 2008 Jan 23.
7
Anti-inflammatory therapy reduces total costs of asthma care compared with bronchodilation: the Asthma Outcomes Registry.与支气管扩张治疗相比,抗炎治疗可降低哮喘护理的总成本:哮喘结局登记研究。
Am J Manag Care. 2000 Sep;6(9):1045-50.
8
Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.布地奈德早期干预轻度持续性哮喘的成本效益分析
J Allergy Clin Immunol. 2003 Dec;112(6):1229-36. doi: 10.1016/j.jaci.2003.09.025.
9
EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.EXCEL:一项比较沙美特罗/丙酸氟替卡松与福莫特罗/布地奈德联合用药治疗成人持续性哮喘的随机试验。
Respir Med. 2006 Jul;100(7):1152-62. doi: 10.1016/j.rmed.2006.03.001. Epub 2006 May 3.
10
Real-life prospective study on asthma control in Italy: cross-sectional phase results.意大利真实世界哮喘控制的前瞻性研究:横断面阶段结果。
Respir Med. 2012 Feb;106(2):205-14. doi: 10.1016/j.rmed.2011.10.001. Epub 2011 Oct 28.

引用本文的文献

1
Effectiveness of biological therapy in severe asthma: a retrospective real-world study.生物疗法在重度哮喘中的有效性:一项回顾性真实世界研究。
Croat Med J. 2025 Feb 28;66(1):3-12. doi: 10.3325/cmj.2025.66.3.
2
Understanding and controlling asthma in Latin America: A review of recent research informed by the SCAALA programme.拉丁美洲哮喘的认识与控制:基于SCAALA项目的近期研究综述
Clin Transl Allergy. 2023 Mar;13(3):e12232. doi: 10.1002/clt2.12232.
3
Closing gaps in asthma care in India - World Asthma Day 2022.缩小印度哮喘护理差距——2022年世界哮喘日
Indian J Med Res. 2022 Jul;156(1):6-9. doi: 10.4103/ijmr.ijmr_893_22.
4
Prospective study of factors associated with asthma attack recurrence (ATTACK) in children from three Ecuadorian cities during COVID-19: a study protocol.前瞻性研究 COVID-19 期间厄瓜多尔三个城市儿童哮喘发作复发(ATTACK)相关因素的研究方案。
BMJ Open. 2022 Jun 16;12(6):e056295. doi: 10.1136/bmjopen-2021-056295.
5
Evaluating the effect of childhood and adolescence asthma on the household economy.评估儿童和青少年哮喘对家庭经济的影响。
J Pediatr (Rio J). 2022 Sep-Oct;98(5):490-495. doi: 10.1016/j.jped.2021.12.010. Epub 2022 Feb 25.
6
An expert review on breaking barriers in severe asthma in Brazil: Time to act.巴西专家综述:打破重症哮喘治疗困境刻不容缓。
Chron Respir Dis. 2021 Jan-Dec;18:14799731211028259. doi: 10.1177/14799731211028259.
7
Association between early bronchiolitis and the development of childhood asthma: a meta-analysis.早期细支气管炎与儿童哮喘发展的关系:荟萃分析。
BMJ Open. 2021 May 28;11(5):e043956. doi: 10.1136/bmjopen-2020-043956.
8
Time trend of Brazilian hospital admissions and deaths due to asthma among children and teenagers, 1998-2019.1998-2019 年巴西儿童和青少年因哮喘住院和死亡的时间趋势。
PLoS One. 2021 Mar 15;16(3):e0248472. doi: 10.1371/journal.pone.0248472. eCollection 2021.
9
2020 Brazilian Thoracic Association recommendations for the management of asthma.2020 年巴西胸科协会哮喘管理建议。
J Bras Pneumol. 2020 Mar 2;46(1):e20190307. doi: 10.1590/1806-3713/e20190307. eCollection 2020.
10
A strategy for measuring health outcomes and evaluating impacts of interventions on asthma and COPD-common chronic respiratory diseases in Global Alliance against Chronic Respiratory Diseases (GARD) countries.一种针对全球抗击慢性呼吸道疾病联盟(GARD)国家中哮喘和慢性阻塞性肺疾病(COPD)这两种常见慢性呼吸道疾病的健康结果测量及干预措施影响评估策略。
J Thorac Dis. 2018 Aug;10(8):5170-5177. doi: 10.21037/jtd.2018.08.100.